Avoro/Behzad Aghazadeh Report 3.625M-Share Position in uniQure

Rhea-AI Filing Summary

Avoro Capital Advisors LLC and Behzad Aghazadeh report holding 3,625,000 ordinary shares of uniQure N.V., representing 6.6% of the outstanding class. The percentage is calculated using 54,748,496 ordinary shares outstanding as of May 6, 2025. The filing states the shares were acquired and are held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and that the reporting persons have sole voting and sole dispositive power over the reported shares. The statement also notes the filing should not be construed as an admission of beneficial ownership for Section 13 purposes. Avoro Life Sciences Fund LLC is identified as having the right to receive dividends or sale proceeds for the position.

Positive

• Material stake disclosed: 3,625,000 shares representing 6.6% of uniQure's outstanding ordinary shares
• Sole voting and dispositive power: Reporting persons state they have sole authority to vote and dispose of the reported shares

Negative

• None.

Insights

Financial Analyst

TL;DR: Avoro and Dr. Aghazadeh disclose a material passive stake of 3.625M shares (6.6%) in uniQure, with sole voting and dispositive power.

The Schedule 13G reports a meaningful >5% position held for investment purposes, based on 54,748,496 shares outstanding as of May 6, 2025. The reporting persons assert sole voting and dispositive authority for 3,625,000 shares, indicating centralized position control within the adviser structure. Because the filing is on Schedule 13G, it represents a passive intent disclosure rather than an activist or control-seeking statement. This is material to investors as a significant ownership stake but does not, by itself, signal change in corporate control or strategy.

Corporate Governance Expert

TL;DR: The filing identifies the portfolio manager and adviser as holders of a 6.6% passive stake, and clarifies the fund holds dividend/proceeds rights.

The document names Avoro Capital Advisors LLC as the investment adviser and Behzad Aghazadeh as portfolio manager and controlling person of Avoro. It specifies that Avoro Life Sciences Fund LLC has the right to receive dividends or sale proceeds from the position exceeding 5% of the class. There is no group designation, no shared voting/dispositive power, and the filing expressly characterizes the holding as for investment purposes, which is consistent with routine 13G disclosures rather than active governance engagement.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

uniQure N.V.

(Name of Issuer)

Ordinary Shares, par value EUR0.05 per share

(Title of Class of Securities)

N90064101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. N90064101

1

Names of Reporting Persons

Avoro Capital Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,625,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,625,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,625,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.6 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. N90064101

1

Names of Reporting Persons

Behzad Aghazadeh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,625,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,625,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,625,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.6 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: uniQure N.V.
(b)	Address of issuer's principal executive offices: Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired the ordinary shares, par value EUR0.05 per share ("Ordinary Shares") of uniQure N.V., a public limited liability company incorporated under the laws of the Netherlands (the "Issuer"), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.
(c)	Citizenship: Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen.
(d)	Title of class of securities: Ordinary Shares, par value EUR0.05 per share
(e)	CUSIP No.: N90064101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon 54,748,496 Ordinary Shares outstanding as of May 6, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 9, 2025.
(b)	Percent of class: 6.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Ordinary Shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Avoro Capital Advisors LLC

Signature:	/s/ Scott Epstein
Name/Title:	Scott Epstein, Chief Financial Officer & Chief Compliance Officer
Date:	08/14/2025

Behzad Aghazadeh

Signature:	/s/ Behzad Aghazadeh
Name/Title:	Behzad Aghazadeh, Individually
Date:	08/14/2025

Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

How many QURE shares does Avoro report owning?

Avoro reports owning 3,625,000 ordinary shares, equal to 6.6% of the class.

Who filed the Schedule 13G for QURE?

The filing was made jointly by Avoro Capital Advisors LLC and Behzad Aghazadeh (portfolio manager).

Does the filer have voting or dispositive power over the QURE shares?

Yes. The filing states sole voting power and sole dispositive power for 3,625,000 shares.

On whose behalf are the shares held?

The shares are held on behalf of Avoro Life Sciences Fund LLC, which has the right to receive dividends or sale proceeds.

How was the 6.6% ownership percentage calculated?

The percentage uses 54,748,496 ordinary shares outstanding reported by the issuer as of May 6, 2025.